MEI Pharma urges shareholders to vote FOR Infinity merger ahead of July 23 special meeting

Lite Strategy, Inc.

MEI mailed letter to shareholders on July 17, 2023, pleading vote FOR the Infinity (INFI) merger at the July 23 special meeting.
Combined company would hold three clinical-stage assets: Eganelisib, Voruciclib, ME-344 with data catalysts in 6-24 months.
ISS and Glass Lewis both recommend FOR; ISS reiterated its support as recently as July 14, 2023.
MEI claims the deal creates a well-capitalized pipeline and leverages the clinical expertise of both teams.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.